Chardan Capital Maintains Buy on EyePoint Pharmaceuticals, Maintains $28 Price Target
EyePoint Pharmaceuticals, Inc. +27.58% Pre
EyePoint Pharmaceuticals, Inc. EYPT | 12.12 11.34 | +27.58% -6.44% Pre |
Chardan Capital analyst Daniil Gataulin maintains EyePoint Pharmaceuticals (NASDAQ:
EYPT) with a Buy and maintains $28 price target.